Tricyclic antidepressants, QT interval prolongation, and torsade de pointes

Psychosomatics

Volumn 45, Issue 5, 2004, Pages 371-377

  Vieweg, W Victor R ^a   Wood, Mark A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; CYCLOBENZAPRINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; DROPERIDOL; ENCAINIDE; FLECAINIDE; FLUCONAZOLE; FLUOXETINE; IMIPRAMINE; LOXAPINE; MAPROTILINE; MEXILETINE; MORACIZINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PHENOTHIAZINE; PROPAFENONE; PROTRIPTYLINE; QUINIDINE; SERTRALINE; THIORIDAZINE; TOCAINIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE;

AGE; BRUGADA SYNDROME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG OVERDOSE; GENDER; HEART ARREST; HEART DEATH; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTHYROIDISM; INTOXICATION; LONG QT SYNDROME; METABOLIC DISORDER; PERIPHERAL EDEMA; PRESCRIPTION; QT PROLONGATION; REVIEW; RISK FACTOR; SEIZURE; SYNCOPE; TORSADE DES POINTES;

EID: 4444345419     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.45.5.371     Document Type: Review

References (45)

1. Morganroth J, Goin JE: Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation 1991; 84:1977-1983
2. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology: The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84:1831-1851
3. Cardiac Arrhythmia Pilot Study (CAPS) investigators: Effects of encainide, flecainide, imipramine, and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol 1988; 61:501-509
4. Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG: Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 1993; 270:2451-2455
5. Glassman AH, Roose SP, Bigger JT Jr: The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. JAMA 1993; 269:2673-2675
6. Darpo B: Spectrum of drugs prolonging QT interval and the incidence of torsade de pointes. Eur Heart J Suppl 2001; 3(suppl K):K70-K80
7. De Ponti F, Poluzzi E, Montanaro N: Organizing evidence on QT prolongation and occurrence of torsade de pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001; 57:185-209
8. Burckhardt D, Raeder E, Miller V, Imhol P, Nebauer H: Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA 1978; 239:213-216
9. Pinder RM, Brogden RN, Speight TM, Avery GS: Maprotiline: a review of its pharmacologic properties and therapeutic efficacy in mental depressive states. Drugs 1977; 13:321-352
10. Sims ACP: Comparison of the efficacy of sustained-release amitriptyline with maprotiline in the treatment of depressive illness. Curr Med Res Opin 1980; 6:534-539
11. Dorsey ST, Biblo LA: Prolonged QT interval and torsade de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 2000; 18:227-229
12. Davison ET: Amitriptyline-induced torsade de pointes: successful therapy with atrial pacing. J Electrocardiol 1985; 18:299-302
13. Manikoth P, Subramanyan R, Menon S, Al Khusaiby SM: A child with cardiac arrhythmia and convulsions. Lancet 1999; 354:2046
14. Jerjes Sanchez Diaz C, Garcia Hernandez N, Gonzalez Carmona VM, Rosado Buzzo A: helicoidal ventricular tachycardia caused by amitriptyline. Arch Inst Cardiol Mex 1985; 55:353-356
15. Flugelman MY, Pollack S, Hammerman H, Riss E, Barzilai D: Congenital prolongation of Q-T interval: a family study of three generations. Cardiology 1982; 69:170-174
16. Strasberg B, Coelho A, Welch W, Swiryn S, Bauemfeind R, Rosen K: Doxepin induced torsade de pointes. Pacing Clin Electrophysiol 1982; 5:873-877
17. Alter P, Tontsch D, Grimm W: Doxepin-induced torsade de pointes tachycardia. Ann Intern Med 2001; 135:384-385
18. Herrmann HC, Kaplan LM, Bierer BE: QT prolongation and torsade de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 1983; 51:904-906
19. Curtis RA, Giacona N, Burrows D, Bauman JL, Schaffer M: Fatal maprotiline intoxication. Drug Intell Clin Pharm 1984; 18:716-720
20. Rialan A, Richard M, Deutsch P, Ouattara B: Torsade de pointes in a patient under long-term maprotiline therapy: apropos of a case. Ann Cardiol Angeiol (Paris) 1996; 45:123-125
21. Lentini S, Rao ML, Schroder R, Luderitz B, Bauriedel G: QT prolongation and torsade de pointes tachycardia during therapy with maprotiline: differential diagnostic and therapeutic aspects. Dtsch Med Wochenschr 2001; 126:1396-1400
22. Casazza F, Fiorista F, Rustici A, Brambilla G: Torsade de pointes caused by tricyclic antidepressive agents: description of a clinical case. G Ital Cardiol 1986; 16:1058-1061
23. Michalets EL, Smith LK, Van Tassel ED: Torsade de pointes resulting from the addition of droperidol to an existing cytochrone P450 drug interaction. Ann Pharmacother 1998; 32:761-765
24. Krikler DM, Curry PVL, Evans TR: Torsade de pointes; an atypical ventricular tachycardia. Br Heart J 1976; 38:311
25. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN: The QT interval. Prog Cardiovasc Dis 2001; 43:1-45
26. Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ, Birmaher B, Goldblatt A: Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35:1491-1501
27. + channel. J Cardiovasc Pharmacol 1998; 32:521-526
28. + channel by the antidepressant drug amitriptyline. Br J Pharmacol 2000; 129:1474-1480
29. + current activation in guinea pig ventricular myocytes. Circ Res 1994; 74:687-699
30. Clements-Jewery H, Curtis MJ: Actions of antipsychotic drugs on ventricular action potential and ion channels, in Cardiovascular Risk Associated With Schizophrenia and Its Treatment. Edited by Camm J. London, Galliard Healthcare Communications, 2003, pp 82-100
31. US Food and Drug Administration: Center for Drug Evaluation and Research Briefing Information for Psychopharmacologic Drugs Advisory Committee Meeting, July 2000. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf
32. US Food and Drug Administration Advisory Committee: Zeldox capsules (ziprasidone): summary of efficacy and safety and overall benefit risk relationship. Bethesda, Md, US Food and Drug Administration, 2000
33. Stahl SM: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 2nd ed. Cambridge, UK, Cambridge University Press, 2000
34. Vieweg WVR: Strategies to prevent fatal arrhythmias with antipsychotics. Current Psychiatry 2002; 1(5):10-21
35. Mehtonen O-P, Aranko K, Malkonen L, Vapaatalo H: A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991; 84:58-64
36. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL: QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048-1052
37. Spiller HA, Winter ML, Mann KV, Borys DJ, Muir S, Krenzelok EP: Five-year multicenter retrospective review of cyclobenzaprine toxicity. J Emerg Med 2001; 13:781-785
38. Brugada P, Brugada J: Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol 1992; 20:1391-1396
39. Naccarelli GV, Antzelevitch C: The Brugada syndrome: clinical, genetic, cellular, and molecular abnormalities. Am J Med 2001; 110:573-581
40. Antzelevitch C: The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001; 12:268-272
41. Antzelevitch C, Brugada P, Brugada J, Brugada R, Shimizu W, Gussak I, Perez Riera AR: Brugada syndrome: a decade of progress. Circ Res 2002; 91:1114-1118
42. Bolognesi R, Tsialtas D, Vasini P, Conti M, Manca C: Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am J Cardiol 1997; 79:242-245
43. Goldgran-Toledano D, Sideris G, Kevorkian J: Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 2002; 346:1591-1592
44. Rouleau F, Asfar P, Boulet S, Dube L, Dupuis M, Alquier P, Victor J: Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J Cardiovasc Electrophysiol 2001; 12:61-65
45. Babaliaros VC, Hurst JW: Tricyclic antidepressants and the Brugada syndrome: an example of Brugada waves appearing after the administration of desipramine. Clin Cardiology 2002; 25:395-398